Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Moleculin Biotech (MBRX) Debt to Equity (2017 - 2022)

Moleculin Biotech's Debt to Equity history spans 6 years, with the latest figure at $0.0 for Q4 2022.

  • Quarterly results put Debt to Equity at $0.0 for Q4 2022, up 19.42% from a year ago — trailing twelve months through Dec 2022 was $0.0 (up 19.42% YoY), and the annual figure for FY2022 was $0.0, up 19.42%.
  • Debt to Equity for Q4 2022 was $0.0 at Moleculin Biotech, down from $0.0 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $0.36 in Q3 2019 to a low of $0.0 in Q1 2021.
  • The 5-year median for Debt to Equity is $0.01 (2020), against an average of $0.06.
  • The sharpest move saw Debt to Equity soared 1358.04% in 2019, then crashed 98.1% in 2020.
  • Year by year, Debt to Equity stood at $0.01 in 2018, then crashed by 49.59% to $0.01 in 2019, then crashed by 30.92% to $0.0 in 2020, then plummeted by 68.58% to $0.0 in 2021, then increased by 19.42% to $0.0 in 2022.
  • According to Business Quant data, Debt to Equity over the past three periods came in at $0.0, $0.0, and $0.0 for Q4 2022, Q3 2022, and Q2 2022 respectively.